<p>擁有大量資金的投資者對 <strong>AbbVie</strong> (NYSE: ABBV) 持樂觀態度。</p>
<p>而散户交易者應該知道這一點。</p>
<p>我們今天注意到這一點，當交易出現在我們在 Benzinga 跟蹤的公開可用期權歷史記錄中。</p>
<p>無論這些是機構還是僅僅是富有的個人，我們都不知道。但當 ABBV 發生如此重大的事情時，通常意味着有人知道即將發生什麼。</p>
<p>那麼我們如何知道這些投資者剛剛做了什麼呢？</p>
<p>今天，Benzinga 的期權掃描儀發現了 16 筆不尋常的 AbbVie 期權交易。</p>
<p>這並不正常。</p>
<p>這些大資金交易者的整體情緒在 43% 看漲和 43% 看跌之間分裂。</p>
<p>在我們發現的所有特殊期權中，有 2 筆是看跌期權，總金額為 $97,520，14 筆是看漲期權，總金額為 $1,449,383。</p>
<h3>預期價格變動</h3>
<p>在評估交易量和未平倉合約後，很明顯主要市場參與者正在關注 AbbVie 的價格區間在 $120.0 到 $250.0 之間，涵蓋了過去三個月。</p>
<h3>交易量與未平倉合約發展</h3>
<p>查看交易量和未平倉合約是對股票進行盡職調查的一個有洞察力的方法。</p>
<p>這些數據可以幫助你跟蹤 AbbVie 期權在特定行權價的流動性和興趣。</p>
<p>下面，我們可以觀察到在過去 30 天內，AbbVie 在 $120.0 到 $250.0 的行權價範圍內的看漲和看跌期權的交易量和未平倉合約的演變。</p>
<h3>AbbVie 30 天期權交易量與興趣快照</h3>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766001684_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="期權看漲圖表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766001684_0.png"/></p>
<h3>發現的最大期權：</h3>
<table>
<thead>
<tr>
<th><strong>符號</strong></th>
<th><strong>看跌/看漲</strong></th>
<th><strong>交易類型</strong></th>
<th><strong>情緒</strong></th>
<th><strong>到期日</strong></th>
<th><strong>賣出價</strong></th>
<th><strong>買入價</strong></th>
<th><strong>價格</strong></th>
<th><strong>行權價</strong></th>
<th><strong>總交易價格</strong></th>
<th><strong>未平倉合約</strong></th>
<th align="right"><strong>交易量</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>看漲</td>
<td>掃描</td>
<td>看跌</td>
<td>03/20/26</td>
<td>$15.1</td>
<td>$14.6</td>
<td>$14.66</td>
<td>$220.00</td>
<td>$293.4K</td>
<td>1.1K</td>
<td align="right">461</td>
</tr>
<tr>
<td>ABBV</td>
<td>看漲</td>
<td>掃描</td>
<td>看漲</td>
<td>01/16/26</td>
<td>$4.55</td>
<td>$4.45</td>
<td>$4.55</td>
<td>$230.00</td>
<td>$226.5K</td>
<td>5.7K</td>
<td align="right">638</td>
</tr>
<tr>
<td>ABBV</td>
<td>看漲</td>
<td>掃描</td>
<td>看跌</td>
<td>03/20/26</td>
<td>$14.85</td>
<td>$14.65</td>
<td>$14.7</td>
<td>$220.00</td>
<td>$190.9K</td>
<td>1.1K</td>
<td align="right">261</td>
</tr>
<tr>
<td>ABBV</td>
<td>看漲</td>
<td>掃描</td>
<td>看跌</td>
<td>03/20/26</td>
<td>$14.85</td>
<td>$14.6</td>
<td>$14.72</td>
<td>$220.00</td>
<td>$183.3K</td>
<td>1.1K</td>
<td align="right">6</td>
</tr>
<tr>
<td>ABBV</td>
<td>看漲</td>
<td>掃描</td>
<td>看跌</td>
<td>03/20/26</td>
<td>$14.85</td>
<td>$14.7</td>
<td>$14.75</td>
<td>$220.00</td>
<td>$173.9K</td>
<td>1.1K</td>
<td align="right">579</td>
</tr>
</tbody>
</table>
<h3>關於 AbbVie</h3>
<p>AbbVie 是一家制藥公司，強烈關注免疫學（包括 Humira、Skyrizi 和 Rinvoq）和腫瘤學（包括 Imbruvica 和 Venclexta）。該公司於 2013 年初從 Abbott 分拆而出。2020 年收購 Allergan 增加了多個新產品和藥物，包括 Botox。2024 年收購 Cerevel（神經科學）和 ImmunoGen（腫瘤學）進一步補充了 AbbVie 的產品組合。</p>
<p>在分析了與 AbbVie 相關的期權活動後，我們轉向更仔細地觀察公司的自身表現。</p>
<h3>AbbVie 目前的狀況如何？</h3>
<ul>
<li>ABBV 的交易量為 2,394,007，價格上漲 0.97%，達到 $225.83。</li>
<li>當前 RSI 值表明該股票在超買和超賣之間處於中性狀態。</li>
<li>下一次財報預計在 44 天后發佈。</li>
</ul>
<h3>專家對 AbbVie 的看法</h3>
<p>2 位市場專家最近對該股票發佈了評級，目標價格共識為 $267.0。</p>
<p><strong>在短短 20 天內將 $1000 變成 $1270？</strong></p>
<p>一位擁有 20 年經驗的專業期權交易員揭示了他的單行圖表技術，顯示何時買入和賣出。複製他的交易，平均每 20 天獲得 27% 的利潤。點擊這裏獲取訪問權限。
* 在評估中保持一致，摩根士丹利的一位分析師對 AbbVie 維持超配評級，目標價格為 $269。
* 在積極的舉措中，滙豐銀行的一位分析師將其評級上調至買入，並將目標價格調整為 $265。</p>
<p>與僅交易股票相比，期權是一種風險更高的資產，但它們具有更高的利潤潛力。嚴肅的期權交易者通過每天學習、逐步進出交易、關注多個指標以及密切關注市場來管理這種風險。</p>
<p>如果你想及時瞭解 AbbVie 最新的期權交易，Benzinga Pro 為你提供實時期權交易警報。</p>

艾伯維

<p>擁有大量資本的投資者對艾伯維（NYSE:ABBV）採取了看漲的態度，這從異常的期權活動中可以看出。Benzinga 的期權掃描儀識別出 16 筆不尋常的交易，情緒分佈為 43% 看漲和 43% 看跌。主要市場參與者關注的價格區間在$120.0 到$250.0 之間。艾伯維是一家制藥公司，目前的交易量為 2,394,007，股價為$225.83。摩根士丹利和滙豐的分析師給予了積極的評級，目標價格分別為$269 和$265</p>

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>AbbVie</strong> (NYSE: ABBV).</p>
<div class="lb-trans"><p>擁有大量資金的投資者對 <strong>AbbVie</strong> (NYSE: ABBV) 持樂觀態度。</p>
</div><p>And retail traders should know.</p>
<div class="lb-trans"><p>而散户交易者應該知道這一點。</p>
</div><p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<div class="lb-trans"><p>我們今天注意到這一點，當交易出現在我們在 Benzinga 跟蹤的公開可用期權歷史記錄中。</p>
</div><p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABBV, it often means somebody knows something is about to happen.</p>
<div class="lb-trans"><p>無論這些是機構還是僅僅是富有的個人，我們都不知道。但當 ABBV 發生如此重大的事情時，通常意味着有人知道即將發生什麼。</p>
</div><p>So how do we know what these investors just did?</p>
<div class="lb-trans"><p>那麼我們如何知道這些投資者剛剛做了什麼呢？</p>
</div><p>Today, Benzinga's options scanner spotted 16 uncommon options trades for AbbVie.</p>
<div class="lb-trans"><p>今天，Benzinga 的期權掃描儀發現了 16 筆不尋常的 AbbVie 期權交易。</p>
</div><p>This isn't normal.</p>
<div class="lb-trans"><p>這並不正常。</p>
</div><p>The overall sentiment of these big-money traders is split between 43% bullish and 43%, bearish.</p>
<div class="lb-trans"><p>這些大資金交易者的整體情緒在 43% 看漲和 43% 看跌之間分裂。</p>
</div><p>Out of all of the special options we uncovered, 2 are puts, for a total amount of $97,520, and 14 are calls, for a total amount of $1,449,383.</p>
<div class="lb-trans"><p>在我們發現的所有特殊期權中，有 2 筆是看跌期權，總金額為 $97,520，14 筆是看漲期權，總金額為 $1,449,383。</p>
</div><h3>Expected Price Movements</h3>
<div class="lb-trans"><h3>預期價格變動</h3>
</div><p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $120.0 and $250.0 for AbbVie, spanning the last three months.</p>
<div class="lb-trans"><p>在評估交易量和未平倉合約後，很明顯主要市場參與者正在關注 AbbVie 的價格區間在 $120.0 到 $250.0 之間，涵蓋了過去三個月。</p>
</div><h3>Volume &amp; Open Interest Development</h3>
<div class="lb-trans"><h3>交易量與未平倉合約發展</h3>
</div><p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<div class="lb-trans"><p>查看交易量和未平倉合約是對股票進行盡職調查的一個有洞察力的方法。</p>
</div><p>This data can help you track the liquidity and interest for AbbVie's options for a given strike price.</p>
<div class="lb-trans"><p>這些數據可以幫助你跟蹤 AbbVie 期權在特定行權價的流動性和興趣。</p>
</div><p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AbbVie's whale activity within a strike price range from $120.0 to $250.0 in the last 30 days.</p>
<div class="lb-trans"><p>下面，我們可以觀察到在過去 30 天內，AbbVie 在 $120.0 到 $250.0 的行權價範圍內的看漲和看跌期權的交易量和未平倉合約的演變。</p>
</div><h3>AbbVie 30-Day Option Volume &amp; Interest Snapshot</h3>
<div class="lb-trans"><h3>AbbVie 30 天期權交易量與興趣快照</h3>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766001684_0.png" alt="Options Call Chart" original-src="https://www.benzinga.com/files/images/story/2025/1766001684_0.png"/></p>
<h3>Biggest Options Spotted:</h3>
<div class="lb-trans"><h3>發現的最大期權：</h3>
</div><table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$15.1</td>
<td>$14.6</td>
<td>$14.66</td>
<td>$220.00</td>
<td>$293.4K</td>
<td>1.1K</td>
<td align="right">461</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.55</td>
<td>$4.45</td>
<td>$4.55</td>
<td>$230.00</td>
<td>$226.5K</td>
<td>5.7K</td>
<td align="right">638</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$14.85</td>
<td>$14.65</td>
<td>$14.7</td>
<td>$220.00</td>
<td>$190.9K</td>
<td>1.1K</td>
<td align="right">261</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$14.85</td>
<td>$14.6</td>
<td>$14.72</td>
<td>$220.00</td>
<td>$183.3K</td>
<td>1.1K</td>
<td align="right">6</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$14.85</td>
<td>$14.7</td>
<td>$14.75</td>
<td>$220.00</td>
<td>$173.9K</td>
<td>1.1K</td>
<td align="right">579</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>符號</strong></th>
<th><strong>看跌/看漲</strong></th>
<th><strong>交易類型</strong></th>
<th><strong>情緒</strong></th>
<th><strong>到期日</strong></th>
<th><strong>賣出價</strong></th>
<th><strong>買入價</strong></th>
<th><strong>價格</strong></th>
<th><strong>行權價</strong></th>
<th><strong>總交易價格</strong></th>
<th><strong>未平倉合約</strong></th>
<th align="right"><strong>交易量</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>看漲</td>
<td>掃描</td>
<td>看跌</td>
<td>03/20/26</td>
<td>$15.1</td>
<td>$14.6</td>
<td>$14.66</td>
<td>$220.00</td>
<td>$293.4K</td>
<td>1.1K</td>
<td align="right">461</td>
</tr>
<tr>
<td>ABBV</td>
<td>看漲</td>
<td>掃描</td>
<td>看漲</td>
<td>01/16/26</td>
<td>$4.55</td>
<td>$4.45</td>
<td>$4.55</td>
<td>$230.00</td>
<td>$226.5K</td>
<td>5.7K</td>
<td align="right">638</td>
</tr>
<tr>
<td>ABBV</td>
<td>看漲</td>
<td>掃描</td>
<td>看跌</td>
<td>03/20/26</td>
<td>$14.85</td>
<td>$14.65</td>
<td>$14.7</td>
<td>$220.00</td>
<td>$190.9K</td>
<td>1.1K</td>
<td align="right">261</td>
</tr>
<tr>
<td>ABBV</td>
<td>看漲</td>
<td>掃描</td>
<td>看跌</td>
<td>03/20/26</td>
<td>$14.85</td>
<td>$14.6</td>
<td>$14.72</td>
<td>$220.00</td>
<td>$183.3K</td>
<td>1.1K</td>
<td align="right">6</td>
</tr>
<tr>
<td>ABBV</td>
<td>看漲</td>
<td>掃描</td>
<td>看跌</td>
<td>03/20/26</td>
<td>$14.85</td>
<td>$14.7</td>
<td>$14.75</td>
<td>$220.00</td>
<td>$173.9K</td>
<td>1.1K</td>
<td align="right">579</td>
</tr>
</tbody>
</table>
</div><h3>About AbbVie</h3>
<div class="lb-trans"><h3>關於 AbbVie</h3>
</div><p>AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.</p>
<div class="lb-trans"><p>AbbVie 是一家制藥公司，強烈關注免疫學（包括 Humira、Skyrizi 和 Rinvoq）和腫瘤學（包括 Imbruvica 和 Venclexta）。該公司於 2013 年初從 Abbott 分拆而出。2020 年收購 Allergan 增加了多個新產品和藥物，包括 Botox。2024 年收購 Cerevel（神經科學）和 ImmunoGen（腫瘤學）進一步補充了 AbbVie 的產品組合。</p>
</div><p>Following our analysis of the options activities associated with AbbVie, we pivot to a closer look at the company's own performance.</p>
<div class="lb-trans"><p>在分析了與 AbbVie 相關的期權活動後，我們轉向更仔細地觀察公司的自身表現。</p>
</div><h3>Where Is AbbVie Standing Right Now?</h3>
<div class="lb-trans"><h3>AbbVie 目前的狀況如何？</h3>
</div><ul>
<li>With a trading volume of 2,394,007, the price of ABBV is up by 0.97%, reaching $225.83.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 44 days from now.</li>
</ul>
<div class="lb-trans"><ul>
<li>ABBV 的交易量為 2,394,007，價格上漲 0.97%，達到 $225.83。</li>
<li>當前 RSI 值表明該股票在超買和超賣之間處於中性狀態。</li>
<li>下一次財報預計在 44 天后發佈。</li>
</ul>
</div><h3>What The Experts Say On AbbVie</h3>
<div class="lb-trans"><h3>專家對 AbbVie 的看法</h3>
</div><p>2 market experts have recently issued ratings for this stock, with a consensus target price of $267.0.</p>
<div class="lb-trans"><p>2 位市場專家最近對該股票發佈了評級，目標價格共識為 $267.0。</p>
</div><p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<div class="lb-trans"><p><strong>在短短 20 天內將 $1000 變成 $1270？</strong></p>
</div><p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.
* Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on AbbVie with a target price of $269.
* In a positive move, an analyst from HSBC has upgraded their rating to Buy and adjusted the price target to $265.</p>
<div class="lb-trans"><p>一位擁有 20 年經驗的專業期權交易員揭示了他的單行圖表技術，顯示何時買入和賣出。複製他的交易，平均每 20 天獲得 27% 的利潤。點擊這裏獲取訪問權限。
* 在評估中保持一致，摩根士丹利的一位分析師對 AbbVie 維持超配評級，目標價格為 $269。
* 在積極的舉措中，滙豐銀行的一位分析師將其評級上調至買入，並將目標價格調整為 $265。</p>
</div><p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<div class="lb-trans"><p>與僅交易股票相比，期權是一種風險更高的資產，但它們具有更高的利潤潛力。嚴肅的期權交易者通過每天學習、逐步進出交易、關注多個指標以及密切關注市場來管理這種風險。</p>
</div><p>If you want to stay updated on the latest options trades for AbbVie, Benzinga Pro gives you real-time options trades alerts.</p>
<div class="lb-trans"><p>如果你想及時瞭解 AbbVie 最新的期權交易，Benzinga Pro 為你提供實時期權交易警報。</p>
</div>

觀察艾伯維最近異常的期權交易活動